Clinical studies have shown that the concurrent administration of the VEGF inhibitor bevacizumab with conventional chemotherapy leads to improved survival and response rates in patients with gastrointestinal cancer, non-small cell lung cancer, and breast cancer [49–51]. Here, VEGFA is linked to non-small cell lung carcinoma.